Eyenovia's Myopia Management segment is centered around the development and commercialization of MicroPine, a microdose formulation designed to slow the progression of pediatric myopia. This segment leverages the Optejet platform to deliver precise and consistent doses of medication, aiming to improve patient compliance and outcomes. Research and development efforts focus on optimizing the formulation and delivery method to maximize efficacy and minimize side effects. Clinical trials are conducted to demonstrate the safety and effectiveness of MicroPine in slowing myopia progression. Strategic partnerships, such as the license agreement with Bausch Health, are crucial for expanding market reach and commercializing MicroPine in key regions. The ultimate goal is to provide an effective and convenient treatment option for children with myopia, reducing the long-term risks associated with high myopia.

The Presbyopia Treatment segment focuses on MicroLine, a Phase III clinical development program aimed at improving near vision in individuals with presbyopia. This segment utilizes the Optejet microdosing technology to deliver precise amounts of medication, offering a potential alternative to traditional reading glasses. Research and development activities are geared towards refining the MicroLine formulation and optimizing the Optejet delivery system for presbyopic patients. Clinical trials are essential for demonstrating the efficacy and safety of MicroLine in improving near vision. Collaborations, such as the agreement with Arctic Vision, are vital for expanding the market presence of MicroLine in regions like China and South Korea. The objective is to provide a convenient and effective solution for presbyopia, enhancing the quality of life for individuals experiencing age-related near vision impairment.

Eyenovia's Mydriasis segment is dedicated to the development of MydCombi, a microdose fixed combination ophthalmic pharmaceutical designed to induce mydriasis for eye exams. This segment aims to provide a more convenient and efficient method for pupil dilation, reducing the time and discomfort associated with traditional dilation drops. Research and development efforts are focused on optimizing the formulation of MydCombi and ensuring the precise delivery of medication through the Optejet system. Clinical trials are conducted to evaluate the safety and efficacy of MydCombi in achieving adequate pupil dilation for comprehensive eye exams. The goal is to offer an improved solution for mydriasis, benefiting both patients and eye care professionals by streamlining the examination process and enhancing patient comfort.